Therefore, CIDP cases with NF155 and CNTN1 antibodies might exhibit similar pathophysiology and clinical manifestations, including distal dominant symptoms and axonal degeneration, differing from the typical CIDP symptoms of proximal and distal muscle weakness with less pronounced axonal degeneration (4). This evidence concerns the gene CNTN1 and chronic inflammatory demyelinating polyradiculoneuropathy.